Skip to main content
. 2019 Nov 29;9:1343. doi: 10.3389/fonc.2019.01343

Figure 3.

Figure 3

IC+CCRT vs. CCRT in the subgroup analysis based on IC regimen [high-risk: TPF (A), PF (B), TP (C); low-risk: TPF (D), PF (E), TP (F)] without adjustment. IC, induction chemotherapy; CCRT, concurrent chemoradiotherapy; TPF, docetaxel–cisplatin−5-fluorouracil; PF, cisplatin−5-fluorouracil; TP, cisplatin−5-fluorouracil.